Industries News.Net

Pacylex Pharmaceuticals Announces the Initiation of a Phase 1 Clinical of PCLX-001, a First-in-class NMT Inhibitor, in Non-Hodgkin's Lymphomas and Solid Tumor Patients


Reportable
14 Sep 2021

Edmonton, AB, September 14, 2021

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

  • PCLX-001 is the first clinical candidate sponsored by Pacylex Pharmaceuticals to reach the clinical stage.
  • Upcoming enrollment of 20-30 patients to begin at the Cross Cancer Institute in Edmonton and expand to Princess Margaret Hospital in Toronto and the BC Cancer Agency in Vancouver.
  • This open label, dose escalation study will examine the safety and tolerability of PCLX-001.

Click image above to view full announcement.

Contacts:

Michael Weickert Ph.D

650-218-1840

michael.weickert@pacylex.com

Source: Pacylex

Distributed by: Reportable, Inc.

Copyright ©1998-2021 Industries News.Net | Mainstream Media Limited - All rights reserved